Tolerating CD47

Abstract

Cluster of differentiation 47 (CD47) occupies the outer membrane of human cells, where it binds to soluble and cell surface receptors on the same and other cells, sculpting their topography and resulting in a pleiotropic receptor-multiligand interaction network. It is a focus of drug development to temper and accentuate CD47-driven immune cell liaisons, although consideration of on-target CD47 effects remain neglected. And yet, a late clinical trial of a CD47-blocking antibody was discontinued, existent trials were restrained, and development of CD47-targeting agents halted by some pharmaceutical companies. At this point, if CD47 can be exploited for clinical advantage remains to be determined. Herein an airing is made of the seemingly conflicting actions of CD47 that reflect its position as a junction connecting receptors and signalling pathways that impact numerous human cell types. Prospects of CD47 boosting and blocking are considered along with potential therapeutic implications for autoimmune diseases and cancer.

Keywords

autoimmunity / cancer / CD47 / checkpoint inhibitor / immunotherapy / SIRPα / TSP1

References

[1] Kaur S, Martin-Manso G, Pendrak ML, Garfield SH, Isenberg JS, Roberts DD. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem. 2010;285(50):38923-38932.

[2] Manna PP, Dimitry J, Oldenborg PA, Frazier WA. CD47 augments Fas/CD95-mediated apoptosis. J Biol Chem. 2005;280(33):29637-29644.

[3] Lindberg FP, Gresham HD, Schwarz E, Brown EJ. Molecular cloning of integrin-associated protein: an immunoglobulin family member with multiple membrane-spanning domains implicated in alpha v beta 3-dependent ligand binding. J Cell Biol. 1993;123(2):485-496.

[4] Reinhold MI, Lindberg FP, Kersh GJ, Allen PM, Brown EJ. Costimulation of T cell activation by integrin-associated protein (CD47) is an adhesion-dependent, CD28-independent signaling pathway. J Exp Med. 1997;185(1):1-11.

[5] Jiang P, Lagenaur CF, Narayanan V. Integrin-associated protein is a ligand for the P84 neural adhesion molecule. J Biol Chem. 1999;274(2):559-562.

[6] Pfeiffer A, Bottcher A, Orso E, et al. Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts. Eur J Immunol. 2001;31(11):3153-3164.

[7] Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci. 2003;23(7):2665-2674.

[8] Kaur S, Elkahloun AG, Singh SP, et al. A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer. Oncotarget. 2016;7(9):10133-10152.

[9] Leclair P, Lim CJ. CD47-independent effects mediated by the TSP-derived 4N1K peptide. PLoS One. 2014;9(5):e98358.

[10] Rebres RA, Green JM, Reinhold MI, Ticchioni M, Brown EJ. Membrane raft association of CD47 is necessary for actin polymerization and protein kinase C theta translocation in its synergistic activation of T cells. J Biol Chem. 2001;276(10):7672-7680.

[11] Wei Y, Zhao M, He T, et al. Quantitatively lighting up the spatial organization of CD47/SIRPalpha immune checkpoints on the cellular membrane with single-molecule localization microscopy. ACS Nano. 2023.

[12] Lv Z, Bian Z, Shi L, et al. Loss of cell surface CD47 clustering formation and binding avidity to SIRPalpha facilitate apoptotic cell clearance by macrophages. J Immunol. 2015;195(2):661-671.

[13] Han X, Wang M, Duan S, et al. Generation of hypoimmunogenic human pluripotent stem cells. Proc Natl Acad Sci U S A. 2019;116(21):10441-10446.

[14] Kaur S, Cicalese KV, Bannerjee R, Roberts DD. Preclinical and clinical development of therapeutic antibodies targeting functions of CD47 in the tumor microenvironment. Antib Ther. 2020;3(3):179-192.

[15] Bouwstra R, van Meerten T, Bremer E. CD47-SIRPalpha blocking-based immunotherapy: current and prospective therapeutic strategies. Clin Transl Med. 2022;12(8):e943.

[16] Pettersen RD, Hestdal K, Olafsen MK, Lie SO, Lindberg FP. CD47 signals T cell death. J Immunol. 1999;162(12):7031-7040.

[17] Manna PP, Frazier WA. The mechanism of CD47-dependent killing of T cells: heterotrimeric Gi-dependent inhibition of protein kinase A. J Immunol. 2003;170(7):3544-3553.

[18] Frazier WA, Gao AG, Dimitry J, et al. The thrombospondin receptor integrin-associated protein (CD47) functionally couples to heterotrimeric Gi. J Biol Chem. 1999;274(13):8554-8560.

[19] Freyberg MA, Kaiser D, Graf R, Vischer P, Friedl P. Integrin-associated protein and thrombospondin-1 as endothelial mechanosensitive death mediators. Biochem Biophys Res Commun. 2000;271(3):584-588.

[20] Manna PP, Frazier WA. CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A. Cancer Res. 2004;64(3):1026-1036.

[21] Kamijo H, Miyagaki T, Takahashi-Shishido N, et al. Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47. Leukemia. 2020;34(3):845-856.

[22] Frazier EP, Isenberg JS, Shiva S, et al. Age-dependent regulation of skeletal muscle mitochondria by the thrombospondin-1 receptor CD47. Matrix Biol. 2011;30(2):154-161.

[23] Roue G, Bitton N, Yuste VJ, et al. Mitochondrial dysfunction in CD47-mediated caspase-independent cell death: rOS production in the absence of cytochrome c and AIF release. Biochimie. 2003;85(8):741-746.

[24] Csanyi G, Yao M, Rodriguez AI, et al. Thrombospondin-1 regulates blood flow via CD47 receptor-mediated activation of NADPH oxidase 1. Arterioscler Thromb Vasc Biol. 2012;32(12):2966-2973.

[25] Nevitt C, McKenzie G, Christian K, et al. Physiological levels of thrombospondin-1 decrease NO-dependent vasodilation in coronary microvessels from aged rats. Am J Physiol Heart Circ Physiol. 2016;310(11):H1842-1850.

[26] Bauer PM, Bauer EM, Rogers NM, et al. Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1. Cardiovasc Res. 2012;93(4):682-693.

[27] Gondois-Rey F, Miller T, Laletin V, et al. CD47-SIRPalpha controls ADCC killing of primary T cells by PMN through a combination of trogocytosis and NADPH oxidase activation. Front Immunol. 2022;13:899068.

[28] Boettcher AN, Cunnick JE, Powell EJ, et al. Porcine signal regulatory protein alpha binds to human CD47 to inhibit phagocytosis: implications for human hematopoietic stem cell transplantation into severe combined immunodeficient pigs. Xenotransplantation. 2019;26(2):e12466.

[29] Fenalti G, Villanueva N, Griffith M, et al. Structure of the human marker of self 5-transmembrane receptor CD47. Nat Commun. 2021;12(1):5218.

[30] Sikic BI, Lakhani N, Patnaik A, et al. First-in-human, first-in-class Phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol. 2019;37(12):946-953.

[31] Alblas J, Honing H, de Lavalette CR, Brown MH, Dijkstra CD, van den Berg TK. Signal regulatory protein alpha ligation induces macrophage nitric oxide production through JAK/STAT- and phosphatidylinositol 3-kinase/Rac1/NAPDH oxidase/H2O2-dependent pathways. Mol Cell Biol. 2005;25(16):7181-7192.

[32] van Beek EM, Zarate JA, van Bruggen R, et al. SIRPalpha controls the activity of the phagocyte NADPH oxidase by restricting the expression of gp91(phox). Cell Rep. 2012;2(4):748-755.

[33] Yao M, Rogers NM, Csanyi G, et al. Thrombospondin-1 activation of signal-regulatory protein-alpha stimulates reactive oxygen species production and promotes renal ischemia reperfusion injury. J Am Soc Nephrol. 2014;25(6):1171-1186.

[34] Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, Roberts DD. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem. 2006;281(36):26069-26080.

[35] Isenberg JS, Romeo MJ, Yu C, et al. Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Blood. 2008;111(2):613-623.

[36] Isenberg JS, Qin Y, Maxhimer JB, et al. Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress. Matrix Biol. 2009;28(2):110-119.

[37] Bauer EM, Qin Y, Miller TW, et al. Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. Cardiovasc Res. 2010;88(3):471-481.

[38] Yao M, Roberts DD, Isenberg JS. Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP. Pharmacol Res. 2011;63(1):13-22.

[39] Khandelwal S, van Rooijen N, Saxena RK. Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation. Transfusion. 2007;47(9):1725-1732.

[40] Gao Q, Chen K, Gao L, Zheng Y, Yang YG. Thrombospondin-1 signaling through CD47 inhibits cell cycle progression and induces senescence in endothelial cells. Cell Death Dis. 2016;7(9):e2368.

[41] Meijles DN, Sahoo S, Al Ghouleh I, et al. The matricellular protein TSP1 promotes human and mouse endothelial cell senescence through CD47 and Nox1. Sci Signal. 2017;10(501):eaaj1784.

[42] Rogers NM, Sharifi-Sanjani M, Yao M, et al. TSP1-CD47 signaling is upregulated in clinical pulmonary hypertension and contributes to pulmonary arterial vasculopathy and dysfunction. Cardiovasc Res. 2017;113(1):15-29.

[43] Rogers NM, Zhang ZJ, Wang JJ, Thomson AW, Isenberg JS. CD47 regulates renal tubular epithelial cell self-renewal and proliferation following renal ischemia reperfusion. Kidney Int. 2016;90(2):334-347.

[44] Kaur S, Soto-Pantoja DR, Stein EV, et al. Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factors. Sci Rep. 2013;3:1673.

[45] Isenberg JS, Hyodo F, Pappan LK, et al. Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia. Arterioscler Thromb Vasc Biol. 2007;27(12):2582-2588.

[46] Ghimire K, Li Y, Chiba T, et al. CD47 promotes age-associated deterioration in angiogenesis, blood flow and glucose homeostasis. Cells. 2020;9(7):1695.

[47] Rogers NM, Roberts DD, Isenberg JS. Age-associated induction of cell membrane CD47 limits basal and temperature-induced changes in cutaneous blood flow. Ann Surg. 2013;258(1):184-191.

[48] Guillon J, Petit C, Moreau M, et al. Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment. Cell Death Dis. 2019;10(3):199.

[49] Sharifi-Sanjani M, Shoushtari AH, Quiroz M, et al. Cardiac CD47 drives left ventricular heart failure through Ca2+-CaMKII-regulated induction of HDAC3. J Am Heart Assoc. 2014;3(3):e000670.

[50] Soto-Pantoja DR, Miller TW, Pendrak ML, et al. CD47 deficiency confers cell and tissue radioprotection by activation of autophagy. Autophagy. 2012;8(11):1628-1642.

[51] Feliz-Mosquea YR, Christensen AA, Wilson AS, et al. Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy. Breast Cancer Res Treat. 2018;172(1):69-82.

[52] Kobayashi M, Ohnishi H, Okazawa H, et al. Expression of Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 in pancreatic beta-Cells and its role in promotion of insulin secretion and protection against diabetes. Endocrinology. 2008;149(11):5662-5669.

[53] Erdem N, Chen KT, Qi M, et al. Thrombospondin-1, CD47, and SIRPalpha display cell-specific molecular signatures in human islets and pancreata. Am J Physiol Endocrinol Metab. 2023;24(4):E347-E357.

[54] Leslie KA, Russell MA, Taniguchi K, Richardson SJ, Morgan NG. The transcription factor STAT6 plays a critical role in promoting beta cell viability and is depleted in islets of individuals with type 1 diabetes. Diabetologia. 2019;62(1):87-98.

[55] Leslie KA, Richardson SJ, Russell MA, Morgan NG. Expression of CD47 in the pancreatic beta-cells of people with recent-onset type 1 diabetes varies according to disease endotype. Diabet Med. 2021;38(12):e14724.

[56] Zhang J, Tan SB, Guo ZG. CD47 decline in pancreatic islet cells promotes macrophage-mediated phagocytosis in type I diabetes. World J Diabetes. 2020;11(6):239-251.

[57] Maimaitiyiming H, Norman H, Zhou Q, Wang S. CD47 deficiency protects mice from diet-induced obesity and improves whole body glucose tolerance and insulin sensitivity. Sci Rep. 2015;5:8846.

[58] Tao HC, Chen KX, Wang X, et al. CD47 deficiency in mice exacerbates chronic fatty diet-induced steatohepatitis through its role in regulating hepatic inflammation and lipid metabolism. Front Immunol. 2020;11:148.

[59] Ghimire K, Kale A, Li J, et al. A metabolic role for CD47 in pancreatic beta cell insulin secretion and islet transplant outcomes. Sci Transl Med. 2023;15(717):eadd2387.

[60] Isenberg JS, Maxhimer JB, Hyodo F, et al. Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury. Am J Pathol. 2008;173(4):1100-1112.

[61] Maxhimer JB, Soto-Pantoja DR, Ridnour LA, et al. Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med. 2009;1(3):3ra7.

[62] Soto-Pantoja DR, Ridnour LA, Wink DA, Roberts DD. Blockade of CD47 increases survival of mice exposed to lethal total body irradiation. Sci Rep. 2013;3:1038.

[63] Stirling ER, Cook KL, Roberts DD, Soto-Pantoja DR. Metabolomic analysis reveals unique biochemical signatures associated with protection from radiation induced lung injury by lack of cd47 receptor gene expression. Metabolites. 2019;9(10):218.

[64] Hao Y, Chen L, Jiang Z. CD47 antibody protects mice from doxorubicin-induced myocardial damage by suppressing cardiomyocyte apoptosis. Exp Ther Med. 2022;23(5):350.

[65] Maruyama T, Kusakari S, Sato-Hashimoto M, et al. Hypothermia-induced tyrosine phosphorylation of SIRPalpha in the brain. J Neurochem. 2012;121(6):891-902.

[66] Li D, Gwag T, Wang S. Absence of CD47 maintains brown fat thermogenic capacity and protects mice from aging-related obesity and metabolic disorder. Biochem Biophys Res Commun. 2021;575:14-19.

[67] Stofega MR, Argetsinger LS, Wang H, Ullrich A, Carter-Su C. Negative regulation of growth hormone receptor/JAK2 signaling by signal regulatory protein alpha. J Biol Chem. 2000;275(36):28222-28229.

[68] Cooper D, Lindberg FP, Gamble JR, Brown EJ, Vadas MA. Transendothelial migration of neutrophils involves integrin-associated protein (CD47). Proc Natl Acad Sci U S A. 1995;92(9):3978-3982.

[69] Lindberg FP, Bullard DC, Caver TE, Gresham HD, Beaudet AL, Brown EJ. Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient mice. Science. 1996;274(5288):795-798.

[70] Liu Y, Merlin D, Burst SL, Pochet M, Madara JL, Parkos CA. The role of CD47 in neutrophil transmigration. Increased rate of migration correlates with increased cell surface expression of CD47. J Biol Chem. 2001;276(43):40156-40166.

[71] Franke K, Pillai SY, Hoogenboezem M, et al. SIRPalpha on mouse B1 cells restricts lymphoid tissue migration and natural antibody production. Front Immunol. 2020;11:570963.

[72] Oh ES, Gu H, Saxton TM, et al. Regulation of early events in integrin signaling by protein tyrosine phosphatase SHP-2. Mol Cell Biol. 1999;19(4):3205-3215.

[73] Roach TI, Slater SE, White LS, et al. The protein tyrosine phosphatase SHP-1 regulates integrin-mediated adhesion of macrophages. Curr Biol. 1998;8(18):1035-1038.

[74] Poole AW, Jones ML. A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail. Cell Signal. 2005;17(11):1323-1332.

[75] Garg M, Wahid M, Khan FD. Regulation of peripheral and central immunity: understanding the role of Src homology 2 domain-containing tyrosine phosphatases, SHP-1 & SHP-2. Immunobiology. 2020;225(1):151847.

[76] Nath PR, Pal-Nath D, Kaur S, et al. Loss of CD47 alters CD8+ T cell activation in vitro and immunodynamics in mice. Oncoimmunology. 2022;11(1):2111909.

[77] Nath PR, Gangaplara A, Pal-Nath D, et al. CD47 expression in natural killer cells regulates homeostasis and modulates immune response to lymphocytic choriomeningitis virus. Front Immunol. 2018;9:2985.

[78] Kaur S, Kuznetsova SA, Pendrak ML, et al. Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1. J Biol Chem. 2011;286(17):14991-15002.

[79] Azcutia V, Routledge M, Williams MR, et al. CD47 plays a critical role in T-cell recruitment by regulation of LFA-1 and VLA-4 integrin adhesive functions. Mol Biol Cell. 2013;24(21):3358-3368.

[80] Navarathna DH, Stein EV, Lessey-Morillon EC, Nayak D, Martin-Manso G, Roberts DD. CD47 promotes protective innate and adaptive immunity in a mouse model of disseminated candidiasis. PLoS One. 2015;10(5):e0128220.

[81] Deuse T, Hu X, Agbor-Enoh S, et al. The SIRPalpha-CD47 immune checkpoint in NK cells. J Exp Med. 2021;218(3):e20200839.

[82] Isenberg JS, Romeo MJ, Abu-Asab M, et al. Increasing survival of ischemic tissue by targeting CD47. Circ Res. 2007;100(5):712-720.

[83] Isenberg JS, Pappan LK, Romeo MJ, et al. Blockade of thrombospondin-1-CD47 interactions prevents necrosis of full thickness skin grafts. Ann Surg. 2008;247(1):180-190.

[84] Isenberg JS, Maxhimer JB, Powers P, Tsokos M, Frazier WA, Roberts DD. Treatment of liver ischemia-reperfusion injury by limiting thrombospondin-1/CD47 signaling. Surgery. 2008;144(5):752-761.

[85] Csanyi G, Feck DM, Ghoshal P, et al. CD47 and Nox1 mediate dynamic fluid-phase macropinocytosis of native LDL. Antioxid Redox Signal. 2017;26(16):886-901.

[86] Noirey N, Rougier N, Andre C, Schmitt D, Vincent C. Langerhans-like dendritic cells generated from cord blood progenitors internalize pollen allergens by macropinocytosis, and part of the molecules are processed and can activate autologous naive T lymphocytes. J Allergy Clin Immunol. 2000;105(6):1194-1201. Pt 1.

[87] Platt CD, Ma JK, Chalouni C, et al. Mature dendritic cells use endocytic receptors to capture and present antigens. Proc Natl Acad Sci U S A. 2010;107(9):4287-4292.

[88] Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science. 2000;288(5473):2051-2054.

[89] Chao MP, Jaiswal S, Weissman-Tsukamoto R, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010;2(63):63ra94.

[90] Luo JQ, Liu R, Chen FM, et al. Nanoparticle-mediated CD47-SIRPalpha blockade and calreticulin exposure for improved cancer chemo-immunotherapy. ACS Nano. 2023;17(10):8966-8979.

[91] Liu J, Wang L, Zhao F, et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS One. 2015;10(9):e0137345.

[92] Bian Z, Shi L, Guo YL, et al. Cd47-Sirpalpha interaction and IL-10 constrain inflammation-induced macrophage phagocytosis of healthy self-cells. Proc Natl Acad Sci U S A. 2016;113(37):E5434-5443.

[93] Liegeois A, Gaillard MC, Ouvre E, Lewin D. Microchimerism in pregnant mice. Transplant Proc. 1981;13(1):1250-1252. Pt 2.

[94] Khosrotehrani K, Johnson KL, Guegan S, Stroh H, Bianchi DW. Natural history of fetal cell microchimerism during and following murine pregnancy. J Reprod Immunol. 2005;66(1):1-12.

[95] Li SS, Liu Z, Uzunel M, Sundqvist KG. Endogenous thrombospondin-1 is a cell-surface ligand for regulation of integrin-dependent T-lymphocyte adhesion. Blood. 2006;108(9):3112-3120.

[96] Gardai SJ, McPhillips KA, Frasch SC, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005;123(2):321-334.

[97] Miller TW, Kaur S, Ivins-O'Keefe K, Roberts DD. Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation. Matrix Biol. 2013;32(6):316-324.

[98] Kaur S, Chang T, Singh SP, et al. CD47 signaling regulates the immunosuppressive activity of VEGF in T cells. J Immunol. 2014;193(8):3914-3924.

[99] Yang G, Geng XR, Liu ZQ, et al. Thrombospondin-1 (TSP1)-producing B cells restore antigen (Ag)-specific immune tolerance in an allergic environment. J Biol Chem. 2015;290(20):12858-12867.

[100] Krispin A, Bledi Y, Atallah M, et al. Apoptotic cell thrombospondin-1 and heparin-binding domain lead to dendritic-cell phagocytic and tolerizing states. Blood. 2006;108(10):3580-3589.

[101] Beppu R, Nakamura K, Miyajima-Uchida H, et al. Soluble thrombospondin-1 suppresses T cell proliferation and enhances IL-10 secretion by antigen presenting cells stimulated with phytohemagglutinin. Immunol Invest. 2001;30(2):143-156.

[102] Isenberg JS, Annis DS, Pendrak ML, et al. Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem. 2009;284(2):1116-1125.

[103] Elberg G, Liraz-Zaltsman S, Reichert F, Matozaki T, Tal M, Rotshenker S. Deletion of SIRPalpha (signal regulatory protein-alpha) promotes phagocytic clearance of myelin debris in Wallerian degeneration, axon regeneration, and recovery from nerve injury. J Neuroinflammation. 2019;16(1):277.

[104] Wang F, Liu YH, Zhang T, et al. Aging-associated changes in CD47 arrangement and interaction with thrombospondin-1 on red blood cells visualized by super-resolution imaging. Aging Cell. 2020;19(10):e13224.

[105] Wu AL, Wang J, Zheleznyak A, Brown EJ. Ubiquitin-related proteins regulate interaction of vimentin intermediate filaments with the plasma membrane. Mol Cell. 1999;4(4):619-625.

[106] Blystone SD, Lindberg FP, LaFlamme SE, Brown EJ. Integrin beta 3 cytoplasmic tail is necessary and sufficient for regulation of alpha 5 beta 1 phagocytosis by alpha v beta 3 and integrin-associated protein. J Cell Biol. 1995;130(3):745-754.

[107] Babic I, Schallhorn A, Lindberg FP, Jirik FR. SHPS-1 induces aggregation of Ba/F3 pro-B cells via an interaction with CD47. J Immunol. 2000;164(7):3652-3658.

[108] Prieto J, Subira ML, Castilla A, Civeira MP, Serrano M. Monocyte disorder causing cellular immunodeficiency: a family study. Clin Exp Immunol. 1990;79(1):1-6.

[109] Vazquez-Doval J, Sanchez-Ibarrola A. Defective mononuclear phagocyte function in systemic lupus erythematosus: relationship of FcRII (CD32) with intermediate cytoskeletal filaments. J Investig Allergol Clin Immunol. 1993;3(2):86-91.

[110] McDonald-Hyman C, Muller JT, Loschi M, et al. The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease. J Clin Invest. 2018;128(10):4604-4621.

[111] Shaebani MR, Stankevicins L, Vesperini D, et al. Effects of vimentin on the migration, search efficiency, and mechanical resilience of dendritic cells. Biophys J. 2022;121(20):3950-3961.

[112] Sosale NG, Rouhiparkouhi T, Bradshaw AM, Dimova R, Lipowsky R, Discher DE. Cell rigidity and shape override CD47's “self”-signaling in phagocytosis by hyperactivating myosin-II. Blood. 2015;125(3):542-552.

[113] Isenberg JS, Hyodo F, Matsumoto K, et al. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood. 2007;109(5):1945-1952.

[114] Adams JC. Formation of stable microspikes containing actin and the 55 kDa actin bundling protein, fascin, is a consequence of cell adhesion to thrombospondin-1: implications for the anti-adhesive activities of thrombospondin-1. J Cell Sci. 1995;108(5):1977-1990. Pt.

[115] Soto-Pantoja DR, Stein EV, Rogers NM, Sharifi-Sanjani M, Isenberg JS, Roberts DD. Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47. Expert Opin Ther Targets. 2013;17(1):89-103.

[116] Bissinger R, Petkova-Kirova P, Mykhailova O, et al. Thrombospondin-1/CD47 signaling modulates transmembrane cation conductance, survival, and deformability of human red blood cells. Cell Commun Signal. 2020;18(1):155.

[117] Burger P, Hilarius-Stokman P, de Korte D, van den Berg TK, van Bruggen R. CD47 functions as a molecular switch for erythrocyte phagocytosis. Blood. 2012;119(23):5512-5521.

[118] Motegi S, Okazawa H, Ohnishi H, et al. Role of the CD47-SHPS-1 system in regulation of cell migration. EMBO J. 2003;22(11):2634-2644.

[119] Subramanian S, Parthasarathy R, Sen S, Boder ET, Discher DE. Species- and cell type-specific interactions between CD47 and human SIRPalpha. Blood. 2006;107(6):2548-2556.

[120] Tseng D, Volkmer JP, Willingham SB, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A. 2013;110(27):11103-11108.

[121] Chroscinski D, Maherali N, Griner E. Reproducibility Project: cancer B: registered report: the CD47-signal regulated protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Elife. 2015;4:e04586.

[122] Horrigan SK, Reproducibility Project: Cancer Biology. Replication Study: the CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Elife. 2017;6:e18173.

[123] Head DJ, Lee ZE, Swallah MM, Avent ND. Ligation of CD47 mediates phosphatidylserine expression on erythrocytes and a concomitant loss of viability in vitro. Br J Haematol. 2005;130(5):788-790.

[124] Devitt A, Moffatt OD, Raykundalia C, Capra JD, Simmons DL, Gregory CD. Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature. 1998;392(6675):505-509.

[125] Ma Y, Qu B, Xia X, et al. Glioma-derived thrombospondin-1 modulates cd14+ cell tolerogenic properties. Cancer Invest. 2015;33(4):152-157.

[126] Wang H, Madariaga ML, Wang S, Van Rooijen N, Oldenborg PA, Yang YG. Lack of CD47 on nonhematopoietic cells induces split macrophage tolerance to CD47null cells. Proc Natl Acad Sci U S A. 2007;104(34):13744-13749.

[127] Rogers NM, Thomson AW, Isenberg JS. Activation of parenchymal CD47 promotes renal ischemia-reperfusion injury. J Am Soc Nephrol. 2012;23(9):1538-1550.

[128] Wang H, Wu X, Wang Y, Oldenborg PA, Yang YG. CD47 is required for suppression of allograft rejection by donor-specific transfusion. J Immunol. 2010;184(7):3401-3407.

[129] Raymond M, Rubio M, Fortin G, et al. Selective control of SIRP-alpha-positive airway dendritic cell trafficking through CD47 is critical for the development of T(H)2-mediated allergic inflammation. J Allergy Clin Immunol. 2009;124(6):1333-1342. e1331.

[130] Chen M, Wang Y, Wang H, Sun L, Fu Y, Yang YG. Elimination of donor CD47 protects against vascularized allograft rejection in mice. Xenotransplantation. 2019;26(2):e12459.

[131] Barros MM, Yamamoto M, Figueiredo MS, et al. Expression levels of CD47, CD35, CD55, and CD59 on red blood cells and signal-regulatory protein-alpha,beta on monocytes from patients with warm autoimmune hemolytic anemia. Transfusion. 2009;49(1):154-160.

[132] Bruce LJ, Ghosh S, King MJ, et al. Absence of CD47 in protein 4.2-deficient hereditary spherocytosis in man: an interaction between the Rh complex and the band 3 complex. Blood. 2002;100(5):1878-1885.

[133] Li DY, Xie SL, Wang GY, Dang XW. CD47 blockade alleviates acute rejection of allogeneic mouse liver transplantation by reducing ischemia/reperfusion injury. Biomed Pharmacother. 2020;123:109793.

[134] Li F, Lv B, Liu Y, et al. Blocking the CD47-SIRPalpha axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells. Oncoimmunology. 2018;7(2):e1391973.

[135] Xiao Z, Banan B, Xu M, et al. Attenuation of ischemia-reperfusion injury and improvement of survival in recipients of steatotic rat livers using CD47 monoclonal antibody. Transplantation. 2016;100(7):1480-1489.

[136] Xiao ZY, Banan B, Jia J, et al. CD47 blockade reduces ischemia/reperfusion injury and improves survival in a rat liver transplantation model. Liver Transpl. 2015;21(4):468-477.

[137] Fang S, Yin H, Song Z, Li R, Xie X, Gu Z. Anti-CD47 antibody eliminates bone tumors in rats. Saudi J Biol Sci. 2019;26(8):2074-2078.

[138] Lee WY, Weber DA, Laur O, et al. The role of cis dimerization of signal regulatory protein alpha (SIRPalpha) in binding to CD47. J Biol Chem. 2010;285(49):37953-37963.

[139] Londino JD, Gulick D, Isenberg JS, Mallampalli RK. Cleavage of signal regulatory protein alpha (SIRPalpha) enhances inflammatory signaling. J Biol Chem. 2015;290(52):31113-31125.

[140] Kusakari S, Ohnishi H, Jin FJ, et al. Trans-endocytosis of CD47 and SHPS-1 and its role in regulation of the CD47-SHPS-1 system. J Cell Sci. 2008;121(8):1213-1223. Pt.

[141] Hayes BH, Zhu H, Andrechak JC, Dooling LJ, Discher DE. Titrating CD47 by mismatch CRISPR-interference reveals incomplete repression can eliminate IgG-opsonized tumors but limits induction of antitumor IgG. PNAS Nexus. 2023;2(8):pgad243.

[142] Dai H, Friday AJ, Abou-Daya KI, et al. Donor SIRPalpha polymorphism modulates the innate immune response to allogeneic grafts. Sci Immunol. 2017;2(12):eaam6202.

[143] Wadhwa M, Meager A, Dilger P, et al. Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations. Immunology. 2000;99(1):113-123.

[144] Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346(7):469-475.

[145] Fehr T, Bachmann MF, Bucher E, et al. Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med. 1997;185(10):1785-1792.

[146] Tacken PJ, de Vries IJ, Gijzen K, et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood. 2005;106(4):1278-1285.

[147] Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res. 2004;21(6):897-903.

[148] Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348(7):601-608.

[149] Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68(11):1739-1745.

[150] Kumar A, Ahmad A, Vyawahare A, Khan R. Membrane trafficking and subcellular drug targeting pathways. Front Pharmacol. 2020;11:629.

[151] Kaur S, Singh SP, Elkahloun AG, Wu W, Abu-Asab MS, Roberts DD. CD47-dependent immunomodulatory and angiogenic activities of extracellular vesicles produced by T cells. Matrix Biol. 2014;37:49-59.

[152] Chauhan S, Danielson S, Clements V, Edwards N, Ostrand-Rosenberg S, Fenselau C. Surface glycoproteins of exosomes shed by myeloid-derived suppressor cells contribute to function. J Proteome Res. 2017;16(1):238-246.

[153] Pizzato HA, Alonso-Guallart P, Woods J, et al. Engineering human pluripotent stem cell lines to evade xenogeneic transplantation barriers. bioRxiv 2023.

[154] Hu X, White K, Olroyd AG, et al. Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques. Nat Biotechnol. 2023. May 8.

[155] Takeuchi K, Ariyoshi Y, Shimizu A, et al. Expression of human CD47 in pig glomeruli prevents proteinuria and prolongs graft survival following pig-to-baboon xenotransplantation. Xenotransplantation. 2021;28(6):e12708.

[156] Wang Z, Guo H, Xu R, Zhao CN, Xia Y. The effects of cell surface CD47 downregulation on ischaemia-reperfusion injury during pig liver transplantation. Int J Exp Pathol. 2021;102(3):140-147.

[157] Nomura S, Ariyoshi Y, Watanabe H, et al. Transgenic expression of human CD47 reduces phagocytosis of porcine endothelial cells and podocytes by baboon and human macrophages. Xenotransplantation. 2020;27(1):e12549.

[158] Inamdar VV, Fitzpatrick EG, Alferiev IS, Levy RJ, Stachelek SJ, Fishbein I. Mitigation of blood borne cell attachment to metal implants through CD47-derived peptide immobilization. J Vis Exp. 2020(166).

[159] Slee JB, Alferiev IS, Nagaswami C, et al. Enhanced biocompatibility of CD47-functionalized vascular stents. Biomaterials. 2016;87:82-92.

[160] Hu X, Gattis C, Olroyd AG, et al. Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice. Sci Transl Med. 2023;15(691):eadg5794.

[161] Ide K, Wang H, Tahara H, et al. Role for CD47-SIRPalpha signaling in xenograft rejection by macrophages. Proc Natl Acad Sci U S A. 2007;104(12):5062-5066.

[162] Mohiuddin MM, Singh AK, Scobie L, et al. Graft dysfunction in compassionate use of genetically engineered pig-to-human cardiac xenotransplantation: a case report. Lancet. 2023;402(10399):397-410.

[163] Denner J, Jhelum H, Hansen S, Kaufer BB. Comparison of methods for the detection of porcine cytomegalovirus/roseolovirus in relation to biosafety monitoring of xenotransplantation products. Xenotransplantation. 2023:e12835.

[164] Xu M, Wang X, Banan B, et al. Anti-CD47 monoclonal antibody therapy reduces ischemia-reperfusion injury of renal allografts in a porcine model of donation after cardiac death. Am J Transplant. 2018;18(4):855-867.

[165] Lin Y, Manning PT, Jia J, et al. CD47 blockade reduces ischemia-reperfusion injury and improves outcomes in a rat kidney transplant model. Transplantation. 2014;98(4):394-401.

[166] Isenberg JS, Shiva S, Gladwin M. Thrombospondin-1-CD47 blockade and exogenous nitrite enhance ischemic tissue survival, blood flow and angiogenesis via coupled NO-cGMP pathway activation. Nitric Oxide. 2009;21(1):52-62.

[167] Gravina A, Tediashvili G, Zheng Y, et al. Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity. Cell Stem Cell. 2023;30(11):1538-1548. e1534.

[168] Avice MN, Rubio M, Sergerie M, Delespesse G, Sarfati M. CD47 ligation selectively inhibits the development of human naive T cells into Th1 effectors. J Immunol. 2000;165(8):4624-4631.

[169] Avice MN, Rubio M, Sergerie M, Delespesse G, Sarfati M. Role of CD47 in the induction of human naive T cell anergy. J Immunol. 2001;167(5):2459-2468.

[170] Dehmani S, Nerriere-Daguin V, Neel M, et al. SIRPgamma-cd47 interaction positively regulates the activation of human T cells in situation of chronic stimulation. Front Immunol. 2021;12:732530.

[171] Montero E, Isenberg JS. The TSP1-CD47-SIRPα interactome: an immune triangle for the checkpoint era. Cancer Immunol Immunother. 2023;72(9):2879-2888. In press.

[172] Oldenborg PA, Gresham HD, Chen Y, Izui S, Lindberg FP. Lethal autoimmune hemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice. Blood. 2002;99(10):3500-3504.

[173] Symeonidis A, Athanassiou G, Psiroyannis A, et al. Impairment of erythrocyte viscoelasticity is correlated with levels of glycosylated haemoglobin in diabetic patients. Clin Lab Haematol. 2001;23(2):103-109.

[174] Jaumouille V, Waterman CM. Physical constraints and forces involved in phagocytosis. Front Immunol. 2020;11:1097.

[175] Thomas MC, MacIsaac RJ, Tsalamandris C, et al. Anemia in patients with type 1 diabetes. J Clin Endocrinol Metab. 2004;89(9):4359-4363.

[176] Isenberg JS, Romeo MJ, Maxhimer JB, Smedley J, Frazier WA, Roberts DD. Gene silencing of CD47 and antibody ligation of thrombospondin-1 enhance ischemic tissue survival in a porcine model: implications for human disease. Ann Surg. 2008;247(5):860-868.

[177] Burgess TL, Amason JD, Rubin JS, et al. A homogeneous SIRPalpha-CD47 cell-based, ligand-binding assay: utility for small molecule drug development in immuno-oncology. PLoS One. 2020;15(4):e0226661.

[178] Miller TW, Amason JD, Garcin ED, et al. Quantitative high-throughput screening assays for the discovery and development of SIRPalpha-CD47 interaction inhibitors. PLoS One. 2019;14(7):e0218897.

[179] Isenberg JS, Roberts DD. THBS1 (thrombospondin-1). Atlas Genet Cytogenet Oncol Haematol. 2020;24(8):291-299.

[180] Isenberg JS, Roberts DD. Thrombospondin-1 in maladaptive aging responses: a concept whose time has come. Am J Physiol Cell Physiol. 2020;319(1):C45-C63.

[181] Miller TW, Isenberg JS, Shih HB, Wang Y, Roberts DD. Amyloid-b inhibits NO-cGMP signaling in a CD36- and CD47-dependent manner. PLos One. 2010;5(12):e15686.

[182] Griffith BP, Goerlich CE, Singh AK, Rothblatt M, Lau CL, Shah A, et al. Genetically modified porcine-to-human cardiac xenotransplantation. N Engl J Med. 2022;387(1):35-44.

[183] Herrmann D, Seitz G, Fuchs J, Armeanu-Ebinger S. Susceptibility of rhabdomyosarcoma cells to macrophage-mediated cytotoxicity. Oncoimmunology. 2012;1(3):279-286.

[184] Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tunors. Proc Natl Acad Sci USA. 2012;109(17):6662-6667.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.